Calamos Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Calamos Advisors’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,349	Closed	-$2.37M	–	1217
2022 Q1	$2.37M	Buy	20,349 +12,688	+166%	+$1.48M	0.01%	893
2021 Q4	$1.15M	Buy	+7,661	New	+$1.03M	﹤0.01%	970
2020 Q4	–	Sell	-42,160	Closed	-$4.79M	–	764
2020 Q3	$4.79M	Buy	42,160 +6,383	+18%	+$671K	0.03%	463
2020 Q2	$3.54M	Buy	35,777 +4,863	+16%	+$388K	0.03%	511
2020 Q1	$1.99M	Buy	+30,914	New	+$2.17M	0.02%	546
2019 Q4	–	Sell	-106,390	Closed	-$6.27M	–	817
2019 Q3	$6.27M	Sell	106,390 -29,957	-22%	-$1.91M	0.03%	457
2019 Q2	$8.8M	Buy	+136,347	New	+$8.8M	0.05%	364

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Calamos Advisors's TNDM Position: Q2 2022 in Review

Calamos Advisors sold out of Tandem Diabetes Care (TNDM) in Q2 2022, closing a stake of 20,349 shares — an estimated $2.37M sold.

Calamos Advisors first reported a position in TNDM in Q2 2019 and held it in 7 quarters. The position peaked at $8.8M in Q2 2019. 330 funds tracked by Wall St. Rank hold TNDM as of Q2 2022.

Calamos Advisors reported no remaining Tandem Diabetes Care position as of Q2 2022 after selling out during the quarter.
Calamos Advisors sold 20,349 Tandem Diabetes Care shares in Q2 2022, an estimated $2.37M.
Calamos Advisors first reported a position in Tandem Diabetes Care in Q2 2019 and held it in 7 quarters.
Calamos Advisors's Tandem Diabetes Care position peaked at $8.8M in Q2 2019.
330 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.